

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM650544

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
ELYSIUM HEALTH, INC.		05/27/2021	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Venture Lending & Leasing IX, Inc.		
Street Address:	104 La Mesa Drive, Suite 102		
City:	Portola Valley		
State/Country:	CALIFORNIA		
Postal Code:	94028		
Entity Type:	Corporation: MARYLAND		
PROPERTY NUMBERS Total: 12			
Property Type	Number	Word Mark	
Registration Number:	4785525	BASIS	
Registration Number:	5558195	E	
Registration Number:	5997324	E	
Registration Number:	4783210	ELYSIUM	
Registration Number:	4785939	ELYSIUM	
Registration Number:	6240861	INDEX BY ELYSIUM HEALTH	
Serial Number:	87426767	CIRCA	
Serial Number:	87430695	CIRCA	
Serial Number:	88079950	ENDEAVOR	
Serial Number:	90018993	FORMAT	
Serial Number:	88621038	INDEX	
Serial Number:	87046347	MESSENGER	
CORRESPONDENCE DATA			
Fax Number:	4157774961		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	4159811400		
Email:	nsust@foxrothschild.com		
Correspondent Name:	Natascha Sust		
Address Line 1:	1 Front Street Suite 3200		

TRADEMARK

Address Line 4: San Francisco, CALIFORNIA 94111

NAME OF SUBMITTER: Jeffrey T. Klugman

SIGNATURE: /Jeffrey T. Klugman/

DATE SIGNED: 05/28/2021

Total Attachments: 14

source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page1.tif
source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page2.tif
source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page3.tif
source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page4.tif
source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page5.tif
source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page6.tif
source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page7.tif
source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page8.tif
source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page9.tif
source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page10.tif
source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page11.tif
source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page12.tif
source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page13.tif
source=21-05-27 IP Security Agreement - Elysium Health(123188365.1)#page14.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "Agreement") is made as of March 27, 2021, between ELYSIUM HEALTH, INC., a Delaware corporation ("Grantor"), and VENTURE LENDING & LEASING IX, INC., a Maryland corporation ("Secured Party").

RECITALS

A. Pursuant to that certain Loan and Security Agreement of even date herewith between Grantor, as borrower, and Secured Party, as lender (as amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), Secured Party has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the "Loans") in the amounts and manner set forth in the Loan Agreement. All capitalized terms used herein without definition shall have the meanings ascribed to them in the Loan Agreement.

B. Secured Party is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Secured Party a security interest in substantially all of Grantor's personal property whether presently existing or hereafter acquired. To that end, Grantor has executed in favor of Secured Party the Loan Agreement granting a security interest in all Collateral, and is executing this Agreement with respect to certain items of Intellectual Property, in particular.

NOW, THEREFORE, THE PARTIES HERETO AGREE AS FOLLOWS:

1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Grantor's present or future Obligations, Grantor hereby grants a security interest to Secured Party, as security, in and to Grantor's entire right, title and interest in, to and under the following Intellectual Property, now owned or hereafter acquired by Grantor or in which Grantor now holds or hereafter acquires any interest (all of which shall collectively be called the "Collateral" for purposes of this Agreement):

(a) Any and all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or of any other country; all registrations, applications and recordings in the United States Copyright Office or in any similar office or agency of the United States, and State thereof or any other country; all continuations, renewals, or extensions thereof; and any registrations to be issued under any pending applications, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) All letters patent of, or rights corresponding thereto in, the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto in, the United States or any other country, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; all reissues, continuations, continuations-in-part or extensions thereof; all petty patents, divisionals, and patents of addition; and all patents to be issued under any such applications, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(c) All trademarks, trade names, corporate names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and any applications in connection therewith, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, and reissues, extensions or renewals thereof, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(d) Any and all claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(e) All licenses or other rights to use any of the Copyrights, Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(f) All amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents;
and

(g) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing the term "Collateral" shall not include: (a) "intent-to-use" trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, but only to the extent the granting of a security interest in such "intent to use" trademarks would be contrary to applicable law or (b) any contract, instrument or chattel paper in which Grantor has any right, title or interest if and to the extent such contract, instrument or chattel paper includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Grantor therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such contract, instrument or chattel paper to enforce any remedy with respect thereto; provided, however, that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such contract, instrument or chattel paper, or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code or principles of equity); provided further that immediately upon the ineffectiveness, lapse or termination of any such provision, the term "Collateral" shall include, and Grantor shall be deemed to have granted a security interest in, all its rights, title and interests in and to such contract, instrument or chattel paper as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Secured Party's unconditional continuing security interest in and to all rights, title and interests of Grantor in or to any payment obligations or other rights to receive monies due or to become due under any such contract, instrument or chattel paper and in any such monies and other proceeds of such contract, instrument or chattel paper.

2. Covenants and Warranties. Grantor represents, warrants, covenants and agrees as follows:

(a) Grantor has rights (as defined in the UCC) in the Collateral, except for Permitted Liens;

(b) During the term of this Agreement, Grantor will not transfer or otherwise encumber any interest in the Collateral, except for Permitted Liens and except for transfers otherwise permitted under the Loan Agreement;

(c) To its knowledge, each of the material Patents is valid and enforceable, and no material part of the Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made that any material part of the Collateral violates the rights of any third party;

(d) **Grantor shall deliver to Secured Party within thirty (30) days of the last day of each fiscal quarter, a report signed by Grantor, in form reasonably acceptable to Secured Party, listing (i) any applications or registrations that Grantor has made or filed in respect of any patents, copyrights or trademarks, (ii) the status of any outstanding applications or registrations and (iii) any material change in the composition of the Collateral;**

(e) Grantor shall use reasonable commercial efforts to (i) protect, defend and maintain the validity and enforceability of the Trademarks, Patents and Copyrights material to Grantor's business, (ii) detect infringements of the Trademarks, Patents and Copyrights material to Grantor's business and promptly advise Secured Party in writing of material infringements detected, and (iii) not allow any material Trademarks, Patents or Copyrights material to Grantor's business to be abandoned, forfeited or dedicated to the public unless Grantor deems it to be in the best interest of Grantor's business without the written consent of Secured Party, which consent shall not be unreasonably withheld;

(f) Grantor shall apply for registration (to the extent registerable and not already registered) with the United States Patent and Trademark Office or the United States Copyright Office, as applicable: (i) those intellectual property rights listed on Exhibits A, B and C heretowin thirty (30) days of the date of this Agreement; and (ii) those additional intellectual property rights developed or aquired by Grantor from time to time in connection with any product or service, prior to the sale or licensing of such product or the rendering of such service to any third party (including without limitation revisions or additions to the intellectual property rights listed on such Exhibits A, B and C), except, in each case, with respect to such rights that Grantor determines in its sole but reasonable commercial judgment need not be registered to protect its own business interests. Grantor shall, from time to time, execute and file such other instruments, and take such further actions as Secured Party may reasonably request from time to time to perfect or continue the perfection of Secured Party's interest in the Collateral; and

(g) Grantor shall not enter into any agreement that would materially impair or conflict with Grantor's obligations hereunder without Secured Party's prior written consent, which consent shall not be unreasonably withheld or delayed.

3. Further Assurances: Attorney in Fact.

(a) On a continuing basis, Grantor will make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral agreements and filings with the United States Patent and Trademark Office and the Register of Copyrights, and take all such actions as may reasonably be deemed necessary or advisable and are reasonably requested by Secured Party, to perfect Secured Party's security interest in all Copyrights, Patents and Trademarks and otherwise to carry out the intent and purposes of this Agreement, or for assuring and confirming to Secured Party the grant or perfection of a security interest in all Collateral.

(b) Grantor hereby irrevocably appoints Secured Party as Grantor's attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor, from time to time in Secured Party's discretion, to take any of the following actions: (i) to modify, in its sole discretion, this Agreement without first obtaining Grantor's approval of or signature to such modification by amending Exhibits A, B and C, hereof, as appropriate, to include reference to any right, title or interest in any Copyrights, Patents or Trademarks aquired by Grantor after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents or Trademarks in which Grantor no longer has or claims any right, title or interest, (ii) to file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without the signature of Grantor where permitted by law, and (iii) subject to the Forbearance Period, after the occurrence and during the continuance of an Event of Default, to transfer the Collateral into the name of Secured Party or a third party to the extent permitted under the California Uniform Commercial Code.

4. Events of Default. The occurrence of any of the following shall constitute an Event of Default under this Agreement:

- (a) An Event of Default under the Loan Agreement; or
- (b) Grantor breaches in any material respect any warranty or a greement made by Grantor in this Agreement and, as to any breach that is capable of cure, Grantor fails to cure such breach within thirty (30) days

of the sooner to occur of Grantor's receipt of notice of such breach from Secured Party or the date on which such breach first becomes known to a responsible officer of Grantor.

5. Amendments. This Agreement may be amended only by a written instrument signed by both parties hereto, except for amendments permitted under Section 3 hereof to be made by Secured Party alone.

6. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement. This Agreement may be executed by electronic signatures. Grantor and Secured Party expressly agree to conduct the transactions contemplated by this Agreement by electronic means (including, without limitation, with respect to the execution, delivery, storage and transfer of this Agreement by electronic means and to the enforceability of electronic Loan Documents). Delivery of an executed signature page to this Agreement by facsimile or other electronic mail transmission shall be effective as delivery of a manually executed counterpart hereof.


[Signature Pages Follow]

[Signature page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

GRANTOR:

ELYSIUM HEALTH, INC.

By: 
Name: Eric Marcotulli
Title: CEO

Address for Notices:

434 Broadway, 2nd Floor
New York, NY 10013
Attn: General Counsel
Fax #:
Phone #:

SECURED PARTY:

VENTURE LENDING & LEASING IX, INC.

By: _____
Name: _____
Title: _____

Address for Notices:

104 La Mesa Dr., Suite 102
Portola Valley, CA 94028
Attn: Chief Financial Officer
Fax # 650-234-4343
Phone # 650-234-4300

[Signature page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

GRANTOR:

ELYSIUM HEALTH, INC.

By: _____

Name: _____

Title: _____

Address for Notices:

Attn:

Fax #:

Phone #:

SECURED PARTY:

VENTURE LENDING & LEASING IX, INC.

By:  _____

Name: David Wanek _____

Title: President _____

Address for Notices:

104 La Mesa Dr., Suite 102
Portola Valley, CA 94028
Attn: Chief Financial Officer
Fax # 650-234-4343
Phone # 650-234-4300

Patents

Item	Title	Country	App Number	File Date	Status	Pub Date
1.	Nicotinamide Riboside for Use in Treating or Preventing Liver Damage	WO	PCT/US18/22854	2018-03-16	Published and Nationalized	2018-09-20
		IN	201917039157	2019-09-27	Published	2019-12-13
		EU	18715431.5	2019-10-11	Published	2020-01-22
		US	16/494581		Pending	
		CN	201880032403	2018-03-16	Published	2020-02-07
2.	Treating and Preventing Motor Neuron Diseases Using Nicotinamide Riboside	WO	PCT/US18/32932	2018-05-16	Published and Nationalized	2018-11-22
		US	16/614244		Pending	
		CN	201880047570.2	2018-05-16	Published	2020-04-17
		JP	2020-514138 (JP2020520991A)	2018-05-16	Published	2020-07-16
		EU	18803104.1	2018-05-16	Published	2021-03-03
3.	Treating and Preventing Kidney Damage	WO	PCT/US18/28807	2018-04-23	Published and Nationalized	2018-11-01
		US	16/607531	2018-04-23	Published	2020-03-05
		CN	201880041987.8	2018-04-23	Published	2020-02-07
		JP	2020-507509	2018-04-23	Published	2020-06-18
		AU	2018260616	2018-04-23	Published	2019-10-31
EU	18791750.5	2018-04-23	Published	2021-01-20		
4.	Methods and Compositions of Improving Fertility	WO	PCT/US18/28809	2018-04-23	Published	2018-11-01
5.	Methods of Synthesizing Nicotinamide Riboside	WO	PCT/US18/40228	2018-06-29	Published and Nationalized	2019-01-03
		US	16/627583	2018-06-29	Published	2020-05-07
		CN	201880056536.1	2018-06-29	Published	2020-06-19
		JP	2020-500078	2018-06-29	Published	2020-08-31
		CA	3068728	2018-06-29	Published	2019-01-03
6.	Nicotinamide Riboside and Pterostilbene Compositions and Methods for Treatment of Skin Disorders	US	15/735066	2016-02-25	Published	2018-12-13
		WO	PCT/US16/19653	2016-02-25	Published and Nationalized	2016-12-15


7.	Nicotinamide Riboside and Pterostilbene Compositions and Methods for Treatment of Neurodegenerative Disorders	CN	201680046668.7	2016-02-25	Published	2018-03-27
		JP	2018-517123	2016-02-25	Published	2019-04-04
		ZA	2018/00056	2016-02-25	Pending-acceptance delayed until April 4, 2022	
		KR	10-2018-7000353	2016-02-25	Published	2018-03-05
		AU	2020286208	2020-12-08	Published	2021-01-07
		CA	2989115 (Divisional)	2016-02-25	Published	2016-12-15
		HK	18113306.2	2018-10-17	Published	2019-07-12
		MX	MX/a/2017/016024	2016-02-25	Pending	
		BR	BR112017026642-3	2016-02-25	Pending	
		IN	201717046835	2017-12-27	Published	2018-02-23
		TW	105118370	2016-06-13	Allowed	2021-01-22
		RU	2017145692		Abandoned	
		EU	16807940.8	2016-02-25	Published	2019-03-27
		US	16/327651	2017-08-22	Published	2019-07-04
WO	PCT/US17/47979	2017-08-22	Published	2018-03-01		
CN	201780064669.9	2017-08-22	Published	2019-07-05		
JP	2019-510843	2017-08-22	Published	2020-10-01		
ZA	2019/01536	2017-08-22	Pending			
KR	10-2019-7008293	2017-08-22	Published	2019-05-07		
AU	2017316614	2017-08-22	Published	2019-03-21		
CA	3034673	2017-08-22	Published	2018-03-01		
MX	MX/a/2019/002211	2017-08-22	Published	2019-10-30		
BR	BR112019003579-6	2017-08-22	Published	2019-05-21		
IN	201917008937	2017-08-22	Published	2019-05-31		
RU			Abandoned			
EU	17844270.3	2017-08-22	Published	2020-03-18		
WO	PCT/US18/66769	2018-12-20	Published and Nationalized	2019-06-27		
US	16/955412	2018-12-20	Published			
CN	201880090063.7		Published	2020-12-01		
JP	2020-534265		Published	2021-02-22		
8.	Crystalline Forms of Nicotinamide Riboside Chloride					

Elysium Health, Inc. IP list

		CA	3086535		Published	2019-06-27
		IN	202017029737	2020-07-13	Pending	
		EU	18892817	2018-12-20	Published	2020-10-28
9.	Methods of Treatment Related to NAD Levels	US	62/760409	2018-11-13	Pending	
		WO	PCT/US19/61146	2019-11-13	Pending	
		US	62/734800	2018-09-21	Pending	
11.	Methods and Compositions for Treating Motor Neuron Diseases	US	62/810728	2019-02-26	Pending	
		WO	PCT/US2020/19600	2020-02-25	Published	2020-09-03
12.	Methods for Wound Treatment	US	62/821779	2019-03-21	Pending	
		WO	PCT/US2020/022596	2020-03-20	Pending	
13.	Methods for Treatment of Viral Infections	US	63/004,958	2020-04-03	Pending	
		WO	PCT/US21/23464	2021-03-22	Pending	

Trademarks

Item	Trademark	Country	Class	App/Int'l Reg Date	App Number	Reg Number	Status
1.	BASIS	Canada	5	2015-06-01	1730670	1072854	Registered
		China	5	2015-05-31	1254707		Pending for refusal appeal
		France	5	2015-05-31	1254707	1254707	Registered
		Greece	5	2015-05-31	1254707	1254707	Registered
		Ireland	5	2015-05-31	1254707	1254707	Registered
		Italy	5	2015-05-31	1254707	1254707	Registered
		Japan	5	2015-05-31	1254707	1254707	Registered
		Mexico	5	2017-08-24	1949285		Pending
		Poland	5	2015-05-31	1254707	1254707	Registered
		Portugal	5	2015-05-31	1254707	1254707	Registered
		South Korea	5	2015-05-31	1254707	1254707	Registered
		Spain	5	2015-05-31	1254707	1254707	Registered
		United Kingdom	5	2015-05-31	1254707	1254707	Registered
		USA	5	2014-12-11	86478053	4785525	Registered
2.	BASIS 贝思思	China	5	2015-05-31	1254707	1254707	Registered (IR Madrid)
			5	2017-07-14	25325691		Invalid
			5	2017-07-14	25325691A	25325691A	Registered
3.	(3D Design)	EU	5	2017-02-14	016366072	016366072	Registered (EUTM)
			5	2017-02-14	016366072		Registered
			5	2017-02-14	UK00916366072	UK00916366072	Registered

4.	CIRCA	Canada	5	2017-10-24	1864399	TMA1034278	Registered
		China	5	2017-10-26	27114551	27114551	Registered
		EU	5	2017-10-24	017386021	017386021	Registered
		Japan	5	2017-10-26	2017-141789	6024543	Registered
		Mexico	5	2017-10-25	1964449		Pending
		South Korea	5	2017-10-30	4020170136659	4013864140000	Registered
		USA	9, 42	2017-04-26	87426767		Abandoned
			5	2017-04-28	87430695		Pending
5.		China	35		41346588	41346588	Registered
			5		41355312	41355312	Registered
		EU	5, 35	2016-09-21	1334559	1334559	Registered
		Japan	5, 35	2016-09-21	1334559	1334559	Registered
		South Korea	5, 35	2016-09-21	1334559	1334559	Registered
		UK	5, 35	2016-09-21	UK00801334559	UK00801334559	Registered
		USA	5	2016-03-24	86983621	5558195	Registered
			35	2016-03-24	86951130	5997324	Registered
		WIPO	5, 35	2016-09-21	1334559	1334559	Registered (IR Madrid)
		Australia	5, 35	2015-07-21	1712508	1257273	Registered
		Brazil	5	2017-03-03	912376376		Pending
			35	2017-03-03	912376414	912376414	Registered
		Cambody ^a	5	2016-08-03	KH/T/2016/7009	KH/64188/17	Registered
		Canada	5, 35	2015-06-01	1730669	TMA1014448	Registered
			9, 41, 42, 45	2017-08-07	1851253	TMA1078959	Registered
		China	5, 35	2015-05-31	1257273		Pending
		EU	5, 35	2015-05-31	1257273	1257273	Registered (EUTM)
			9, 41, 42, 45	2017-08-07	017079633	017079633	Registered (EUTM)
		Hong Kong	5	2016-07-07	303830229	303830229	Registered
		Indonesia	5	2016-08-02	D002016035920	IDM000664668	Registered
6.	ELYSIUM						

7.	ELYSIUM 毅力思安	China	5	2017-07-14	25325705	25325705	Registered					
			8.	ELYSIUM BIOSCIENCES	USA	5, 42	2018-01-09	87748621	Pending			
						9.	ELYSIUM HEALTH	Canada	5, 35	2014-10-28	1700142	Registered
									5	2014-12-11	15907549	Registered
									35	2014-12-11	15907548	Registered
						10.	ENDEAVOR	Canada	5	2015-12-29	1761518	Registered
									5	2018-08-15	88079950	Pending
						11.	FORMAT	USA	5	2017-12-21	1392006	Registered
									5	2017-12-21	1392006	Registered
									5	2017-12-13	1872789	Registered
5	2017-12-20	28214168A	Registered									
	Japan		5, 35	2015-05-31	1257273	1257273	Registered					
			41, 45	2017-08-28	2017-114124	6101327	Registered					
			5, 35	2016-06-24	1257273	1257273	Registered					
			5	2016-06-27	2016061755	2016061755	Registered					
			5	2017-02-17	1866530	1257273	Registered					
					1866531	1257273	Registered					
					1928649	1842237	Registered					
			42	2017-08-07	1928650	1842238	Registered					
			45	2017-08-07	1928650	1842238	Registered					
			5	2017-08-02	0696063-2017	00252829	Registered					
0696065-2017	00101450	Registered										
35	2017-08-02	0696065-2017	00101450	Registered								
5, 35	2015-05-31	1257273	1257273	Registered								
		4020170108075	4020191522149	Registered								
9, 42, 45	2017-08-25	4020170108075	4020191522149	Registered								
5, 35	2015-05-31	1257273	1257253	Registered								
5	2016-06-27	208820		Pending								
5	2016-07-06	105039297	01825942	Registered								
5	2016-07-21	1052434	181101605	Registered								
5, 35	2014-06-11	86307013	4783210	Registered								
		86527497	4785939	Registered								
5, 35	2015-02-06	86527497	4785939	Registered								
5, 35	2016-06-24	1257273	1257273	Registered								
5, 35	2015-05-31	1257273	1257273	Registered (IR Madrid)								
5, 35	2015-05-31	1257273	1257273	Registered								

12.	Index	France	5	2017-12-21	1392006	1392006	Registered
		Italy	5	2017-12-21	1392006	1392006	Registered
		Japan	5	2017-12-18	2017-165753	6096597	Registered
		Mexico	5	2017-12-31	1985191	1863826	Registered
		Poland	5	2017-12-21	1392006	1392006	Registered
		South Korea	5	2017-12-14	4020170160651	4014033690000	Registered
		Spain	5	2017-12-21	1392006	1392006	Registered
		Sweden	5	2017-12-21	1392006	1392006	Registered
		United Kingdom	5	2017-12-21	1392006	1392006	Registered
		USA	5	2020-06-24	90018993		Pending
		Australia	9, 10, 42		2075889		Pending
		Canada	9, 10, 42		2017475		Pending
		13.	Index by Elysium Health	China	42		53132880
	9				53141314		Pending
	10				53152862		Pending
EU	9, 10, 42				018211626	018211626	Registered
UK	9, 10, 42				UK00003475281	UK00003475281	Registered
14.	Matter	USA	9, 10, 42	2019-09-18	88621038		Published for opposition on 2020-08-11
					UK00918211626	UK00918211626	Registered
		Hong Kong	9, 10, 42		305336776	305336776	Registered
		USA	9, 10, 42		88621050	6240861	Registered
13.	Index by Elysium Health	Canada	5		1559810		Pending
		China	5		1559810		Pending
		EU	5		1559810		Pending
		Italy	5		1559810		Pending
		Japan	5		1559810		Pending
					1559810		Pending
		Mexico	5		1559810		Pending

	South Korea	5		1559810		Pending
	UK	5		1559810	1559810	Registered
	USA	5		88867539	6223792	Registered
	WIPO	5		1559810	1559810	Registered
15.	MESSENGER	USA	5	2016-05-23	87046347	Pending

Copyright Registrations

	Name	Full Title	Copyright Number	Date
1.	Elysium Health, Inc.	How Does Basis Work?	PA0002055434	2017
2.	Elysium Health, Inc.	Living In The Future.	PA0002078920	2017